Endometriosis: Recent Advances in 2026 & ENZIAN Classification MRI

The Virtual Clinics
Edition 2026

Endometriosis: Recent Advances

Author: Dr. Sharad Maheshwari MD • imagingsimplified@gmail.com

High-yield revision capsule covering the shift from anatomical to molecular paradigms, new biomarkers, ENZIAN staging, and targeted therapies.

Clinical Vignette

A 32-year-old nulliparous woman presents with a 10-year history of worsening dysmenorrhea, chronic non-cyclic pelvic pain, and deep dyspareunia. She has struggled to conceive for 3 years. Over-the-counter NSAIDs provide minimal relief.

Clinical Reasoning: This constellation of symptoms—cyclical pain, non-cyclical pain, site-specific pain (dyspareunia), and infertility—is the classic hallmark of endometriosis, demanding a comprehensive diagnostic and therapeutic strategy.

Pathophysiology & Core Mechanisms

Cyclical Hemorrhage

Ectopic endometrial tissue responds to hormones, bleeding locally during menstruation.

Chronic Inflammation

Accumulated blood products trigger severe local and systemic immune dysfunction.

Fibrosis & Tethering

Dense stromal components cause architectural distortion, adhesions, and organ tethering.

Evidence Base: Interplay of hemorrhage, inflammation, and fibrosis is central to pathogenesis. Taylor et al., "Endometriosis is a chronic systemic disease" (Lancet, 2021).

Clinical Presentation & Exam

Site-Specific Symptoms

  • Deep Dyspareunia: Pouch of Douglas/Uterosacral involvement.
  • Dyschezia: Rectosigmoid invasion (Deep Endometriosis).
  • Dysuria / Hematuria: Bladder/ureteral involvement.

Key Exam Findings

  • Fixed, retroverted uterus.
  • Nodularity in posterior cul-de-sac.
  • Tenderness along uterosacral ligaments.

Biomarker Note: Serum CA-125 may be elevated but lacks diagnostic specificity.

Evidence Base: Detailed clinical examination guides subsequent imaging. ACOG Practice Bulletin No. 114 (Reaffirmed 2022).

High-Yield Concept Paradigm

Old Paradigm

  • Disease: Purely Anatomical
  • Diagnosis: Laparoscopy (Gold Standard)

New Paradigm (2026)

  • Disease: Molecular + Inflammatory + Fibrotic + Genetic
  • Diagnosis: Biomarkers + MRI + Molecular Imaging

Evidence Base: The shift towards recognizing endometriosis as a systemic, molecular disease is extensively supported in recent literature. Taylor et al., "Endometriosis is a chronic systemic disease" (Lancet, 2021).

1. Genetics (Recent Advances)

Susceptibility Genes

  • WNT4 (Strongest association)
  • GREB1
  • VEZT
  • IL1A, FSHB

Somatic Mutations in Lesions

KRAS ARID1A PIK3CA PTEN

Exam Pearl

Endometriosis is now considered a clonal disease with cancer-like mutations despite being benign.

Evidence Base (Genetics):

2. Salivary microRNA Test

Ziwig Endotest®

(France)

Uses

Saliva sample
109 miRNA panel
AI-based analysis

Performance

Sensitivity >97%
Specificity >93%

NEET PG One-Liner: Most promising non-invasive molecular test = Salivary microRNA testing.

Evidence Base: The ENDOmiRNA study validated the high sensitivity/specificity of the 109-miRNA salivary signature. Recent Clinical Validation Study of Salivary miRNA for Endometriosis (PubMed: 41147827).

3. Imaging & Nuclear Medicine

TVUS

First-line imaging. Best for:

  • Endometrioma
  • Deep infiltrating endometriosis (DIE)

MRI

Best for mapping & surgery. Detects:

  • Bowel & Bladder involvement
  • Ureteric & Pelvic sidewall disease
Hallmark: Detects hemorrhagic components as T1 signal hyperintensity. Deep lesions show a dense stromal component causing architectural distortion and tethering.

New Nuclear Scans

HIGH YIELD

99mTc-Maraciclatide SPECT-CT

Target: αvβ3 integrin & Angiogenesis

Detects: Active lesions, Superficial peritoneal disease

FAPI PET (Research)

Target: Activated fibroblasts

Used for: Assessing fibrotic disease burden

Evidence Base (Molecular Imaging):

ENZIAN for Radiologists

For radiologists, the challenge with ENZIAN isn't remembering A-B-C, but recalling the extended compartments (O, T, FA, FB, FU, FI, FN). Here is a layered memory mastery approach.

Level 1: The Main Disease Map

A = Anovaginal

Area between vagina & rectum.
(Rectovaginal septum, Vagina)

B = Back Ligaments

Posterior supports.
(Torus uterinus, Uterosacral ligaments, Pelvic sidewall)

C = Colon

Bowel involvement.
(Rectum, Rectosigmoid)

Ultra-Short Mnemonic

"A Big Colon Occupies Tubes; FA, FB, FU, FI, FN."

The easiest sequence to recall while actively dictating a report.

Alternative Sentence

"A Big Colon Often Traps Adenomyosis, Bladder, Ureter, Intestine and Nerves."

SM Quick Reporting Card
ARV Septum / Vagina
BTorus / USL
CRectum / Sigmoid
OOvary
TTube
FAAdenomyosis
FBBladder
FUUreter
FIOther Bowel
FNNerves

Medical & Surgical Management

Medical Foundations

  • NSAIDs: First-line for pain management prior to hormonal therapy.
  • Progestins: e.g., Dienogest. Highly effective for long-term symptom suppression.
  • GnRH Agonists: Require "add-back therapy" to mitigate bone mineral density loss and menopausal symptoms.

Surgical & Adjuncts

  • Laparoscopy: Gold standard. Excision of lesions, adhesiolysis, and restoration of anatomy.
  • Fertility-Sparing: Prioritized in patients desiring conception.
  • Multidisciplinary Care: Pelvic floor physical therapy, psychology, and centralized pain management.

Most Important Recent Drug Class

Oral GnRH Antagonists

Elagolix (1st Approved) Relugolix Linzagolix
Oral Admin
Rapid Action
Better Control

Evidence Base (Management):

Prognosis & Complications

Ovarian Cancer Risk

Endometriomas are associated with an increased risk of developing clear cell and endometrioid ovarian carcinomas. This is thought to be driven by chronic inflammation and accumulation of cancer driver mutations (e.g., ARID1A, PIK3CA).

Structural & Functional Complications

  • Infertility: Most common complication, caused by anatomical distortion (adhesions) and hostile inflammatory milieu.
  • Ureteral Compression: Deep infiltrating lesions can cause strictures, hydronephrosis, and eventually chronic kidney disease.
  • Bowel Obstruction: Secondary to severe fibrotic tethering.

Evidence Base: Established epidemiological links exist between endometriosis and specific ovarian cancer subtypes. Kvaskoff et al., "Endometriosis: a high-risk population for major chronic diseases?" (Lancet Psychiatry/Oncol, 2021).

7. Future Precision Medicine Model

Step 1
Salivary miRNA
Step 2
MRI + ENZIAN
Step 3
Molecular Imaging
Step 4
Genetic Profiling
Goal
Personalized Therapy

ENZIAN DIE Calculator

Select lesion sizes to generate ENZIAN string. Superior to rASRM for Deep Infiltrating Endometriosis, as rASRM fails to quantify retroperitoneal, bowel, and bladder disease.

Ref: Keckstein et al. (ENZIAN Classification)

Enzian A0 B0 C0

Revision Table

Strongest genetic linkWNT4
Salivary testZiwig Endotest
Mapping MRI Class.ENZIAN
New nuclear scan99mTc-Maraciclatide
Maraciclatide targetαvβ3 integrin
1st oral GnRH antag.Elagolix
Common mutationsKRAS, ARID1A, PIK3CA, PTEN

High-Yield Flashcards

Click to flip and memorize key concepts.

Memory Trick

W-M-E-M-E

Tap to reveal

  • W = WNT4 (Genetics)
  • M = miRNA saliva test
  • E = ENZIAN MRI staging
  • M = Maraciclatide scan
  • E = Elagolix treatment

Most promising salivary biomarker?

Ziwig Endotest

99mTc-Maraciclatide targets which receptor?

αvβ3 integrin

First oral GnRH antagonist approved?

Elagolix

Most widely used MRI classification for DIE?

ENZIAN

Test Your Knowledge

Endometriosis Q-Bank

NEET PG / INI-CET Pattern MCQs (2026 Updates included)

© 2026 NEET PG Revision Capsule. Built for Medical Excellence.

Comments